Activating the immune system with vaccines or immunotherapy has had a major impact on the prevention and treatment of human diseases. Engineering effective vaccines for respiratory diseases or genetically modified immune cells for cancer treatment has created new challenges in quantifying a functional immune response.
In this webinar, Navin Varadarajan, professor of chemical and biomolecular engineering at the University of Houston, will describe single-cell technology platforms and molecular engineering approaches that his lab has developed to address these problems and how these approaches are being implemented to improve the efficacy of cancer immunotherapy and engineer next-generation mucosal vaccines.
- The use of integrated dynamic and transcriptional single-cell profiling to engineer more potent serial killer chimeric antigen receptor T cells for solid tumors
- The use of single-cell RNA sequencing to demonstrate that the nasal-associated lymphoid tissue (NALT) is an immune inductive site upon immunization with intranasal SARS-CoV-2 subunit vaccines
Sponsored by BD